A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer

@article{Khuri2000ACT,
  title={A controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer},
  author={Fadlo R. Khuri and J. Nemunaitis and I. Ganly and J. Arseneau and I. Tannock and L. Romel and M. Gore and J. Ironside and R. H. MacDougall and C. Heise and B. Randlev and A. Gillenwater and P. Bruso and S. Kaye and Waun Ki Hong and David H. Kirn},
  journal={Nature Medicine},
  year={2000},
  volume={6},
  pages={879-885}
}
  • Fadlo R. Khuri, J. Nemunaitis, +13 authors David H. Kirn
  • Published 2000
  • Medicine
  • Nature Medicine
  • ONYX-015 is an adenovirus with the E1B 55-kDa gene deleted, engineered to selectively replicate in and lyse p53-deficient cancer cells while sparing normal cells. Although ONYX-015 and chemotherapy have demonstrated anti-tumoral activity in patients with recurrent head and neck cancer, disease recurs rapidly with either therapy alone. We undertook a phase II trial of a combination of intratumoral ONYX-015 injection with cisplatin and 5-fluorouracil in patients with recurrent squamous cell… CONTINUE READING

    Figures, Tables, and Topics from this paper.

    Paper Mentions

    INTERVENTIONAL CLINICAL TRIAL
    The purpose of this study is to determine if TACE plus Recombinant Human Adenovirus Type 5 Injection will improve outcome in patients with advanced hepatocellular carcinoma (HCC) not… Expand
    ConditionsHepatocellular Carcinoma
    InterventionDrug, Procedure

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 51 REFERENCES